A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma
Status:
Recruiting
Trial end date:
2027-07-20
Target enrollment:
Participant gender:
Summary
An open-label, multicenter phase Ib/II clinical study to evaluate the safety and efficacy of
LBL-024 combined with etoposide and platinum in the first-line treatment of patients with
advanced neuroendocrine carcinoma (NEC)